Sona Nanotech Inc (TSE:SONA) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sona Nanotech Inc. announced promising results from its preclinical study using Targeted Hyperthermia Therapy to treat colorectal cancer, which showed enhanced response rates when combined with standard immunotherapy. The study revealed that tumors in mice were significantly reduced, with half of them eliminated, demonstrating the potential of the therapy to convert resistant cancers into responsive ones.
For further insights into TSE:SONA stock, check out TipRanks’ Stock Analysis page.